Dimension Expands Board
This article was originally published in Scrip
Dimension Therapeutics, Inc., a company developing liver-directed treatments for diverse genetic disorders, has elected of Dr Georges Gemayel, former executive vice-president of Genzyme Corporation and Arlene M. Morris, former CEO of Syndax Pharmaceuticals, to its board of directors. Dimension has also announced that Donald J. Hayden, Jr. is leaving his position as a member of the board. Previously, Gemayel was executive chair of Vascular Magnetics Inc., Syndexa, and FoldRx Pharmaceuticals, Inc (acquired by Pfizer). And Morris was previously president and CEO of Affymax, Inc.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.